0000000000219232

AUTHOR

Gianluca Tedaldi

showing 2 related works from this author

Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement

2021

An expert consensus panel convened by the Italian Association for Inherited and Familial Gastrointestinal Tumors (Associazione Italiana per lo Studio della Familiarita ed Ereditarieta dei Tumori Gastrointestinali, AIFEG) reviewed the literature and agreed on a number of position statements regarding the definition and management of polyposis coli without an identified pathogenic mutation on the APC or MUTYH genes, defined in the document as NAMP (non-APC/MUTYH polyposis).

Oncologymedicine.medical_specialtyGastrointestinal tumorsColorectal cancerSurgical ManagementColorectal polyposisGermline03 medical and health sciencesCancer Genetic0302 clinical medicineMUTYHInternal medicinemedicineCancer GeneticsPolyposis coliHepatologyPathogenic mutationbusiness.industryColorectal polyposis not associated with APC/MUTYH mutationPolyposis management guidelineGastroenterologyExpert consensusEndoscopic surveillancemedicine.diseaseColorectal cancerConsensus development conference030220 oncology & carcinogenesisCancer Genetics; Colorectal cancer; Colorectal polyposis not associated with APC/MUTYH mutation; Consensus development conference; Endoscopic surveillance; Polyposis management guideline; Surgical Management030211 gastroenterology & hepatologybusiness
researchProduct

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk

2019

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male brea…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismPALB2Diseasemale breast cancerHyperestrogenismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerInternal medicineGenotypeCYP17A1Internal MedicineGenetic predispositionMedicine030212 general & internal medicineskin and connective tissue diseasesEstrogen Receptor Statusmale breast cancer; CYP17A1; CYP1B1; polymorphisms; male breast cancer risklcsh:RC648-665business.industryResearchmedicine.diseasemale breast cancer risk030220 oncology & carcinogenesisMale breast cancerCYP1B1medicine.symptombusinesspolymorphismsEndocrine Connections
researchProduct